Sugi Predict

Sugi Predict / Compounds / SCHEMBL399396

SCHEMBL399396

SCHEMBL399396

Nc1nccn2cncc12

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 1/20 0.48
▸ SRC P12931 1/20 0.44
▸ IDO1 P14902 2/20 0.39
▸ MAPT P10636 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ QPCT Q16769 1/20 0.33
▸ QPCTL Q9NXS2 1/20 0.33
▸ TDO2 P48775 1/20 0.31
▸ CDC7 O00311 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ TBXAS1 P24557 1/20 0.30
▸ NOS3 P29474 1/20 0.30
▸ NOS1 P29475 1/20 0.30
▸ NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30404265 0.98 NUDT1 (0.47) NUDT1SRCIDO1MAPTMAP4K4
SCHEMBL5493377 0.83 NUDT1 (0.39) NUDT1SRCIDO1MAPTCDC7
SCHEMBL1015306 0.75 SRC (0.44) NUDT1SRCIDO1QPCTQPCTL
SCHEMBL1155489 0.75 SRC (0.44) NUDT1SRCIDO1QPCTQPCTL
SCHEMBL31391522 0.75 SRC (0.44) NUDT1SRCIDO1QPCTQPCTL
SCHEMBL1129049 0.75 SRC (0.44) NUDT1SRCIDO1QPCTQPCTL
SCHEMBL30297688 0.72 SRC (0.39) SRCIDO1TDO2TBXAS1
SCHEMBL24198354 0.71 SRC (0.44) SRCIDO1QPCTQPCTLTBXAS1
SCHEMBL21672756 0.71 SRC (0.44) SRCIDO1QPCTQPCTL
SCHEMBL24983628 0.71 SRC (0.44) SRCIDO1QPCTQPCTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118089-A BTK inhibitors 迪哲(江苏)医药股份有限公司 2025-06-10 — — CN claimed
CN-114945574-B BTK inhibitors 迪哲(江苏)医药股份有限公司 2025-02-07 — — CN claimed
CN-111526877-B Compounds and compositions for IRE1 inhibition 奥普提卡拉公司 2023-08-25 — — CN claimed
EP-3675858-B1 IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION OPTIKIRA LLC (US) 2023-04-26 — — EP claimed
EP-4087845-A1 BTK INHIBITORS DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-11-16 — — EP claimed
EP-4061851-A1 METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH PI3 KINASE DELTA INHIBITORS BeiGene, Ltd. (KY) 2022-09-28 — — EP claimed
CN-114945574-A BTK inhibitors 迪哲(江苏)医药股份有限公司 2022-08-26 — — CN claimed
CN-114729050-A Methods of treating cancer using anti-OX 40 antibodies in combination with PI3 kinase delta inhibitors 百济神州有限公司 2022-07-08 — — CN claimed
US-12624039-B2 BTK inhibitors DIZAL (JIANGSU) PHARCEUTICAL CO., LTD. (CN) 2026-05-12 — — US disclosed
US-20260001885-A1 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS MERCK SHARP & DOHME (NL) 2026-01-01 — — US disclosed
EP-4634184-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY Crossfire Oncology Holding B.V. (NL) 2025-10-22 — — EP disclosed
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds HIBERCELL, INC. (US) 2025-06-17 — — US disclosed
CN-120118089-A BTK inhibitors 迪哲(江苏)医药股份有限公司 2025-06-10 — — CN disclosed
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2025-03-06 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
US-20070149521-A1 Bicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 — — WO disclosed
WO-2007064993-A2 BICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-06-07 — — WO disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149521-A1 Bicyclic protein kinase inhibitors CDK1, MAP4K2, MAP4K3 NUDT1 4135/4885SRC 210/4885IDO1 1619/4885
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds MAPKAPK2, MAPK4, MAP3K5 NUDT1 2864/4885SRC 762/4885IDO1 4309/4885
US-20260001885-A1 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS BTK, ABL1, FLT3 NUDT1 3603/4885SRC 11/4885IDO1 1860/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 NUDT1 4348/4885SRC 299/4885IDO1 536/4885
US-20250074911-A1 MACROCYCLIC BTK INHIBITORS BTK, LYN, LCK NUDT1 2285/4885SRC 7/4885IDO1 1885/4885
US-12624039-B2 BTK inhibitors BTK, ABL1, SYK NUDT1 1881/4885SRC 18/4885IDO1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.